As I indicated in my post yesterday, the conversation about compensating kidney donors is heating up. Various email correspondents brought to my attention the latest issue of the American Journal of Bioethics, which has a "target" article by Julian Koplin of Monash University and a number of responses and comments. Koplin argues that the experience of kidney sales in Iran should give pause to advocates of (even) regulated markets in the developed world. A number of the commentators argue that the evidence that he cites from Iran is now outdated, among other things. But the conclusions of the commentators are all over the map, from pro to anti and including appeals for allowing some experimentation to gather more evidence, and arguments against 'crossing the Rubicon' by allowing such trials.
I don't know of an ungated URL where you can read this, but of course if you have electronic access to a University library you can likely download it there.
I don't know of an ungated URL where you can read this, but of course if you have electronic access to a University library you can likely download it there.
Posts
